Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT00004095
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining irinotecan and gemcitabine in treating patients who have unresectable or metastatic solid tumors.

Key Dates

Start date
Aug 31, 1999
Status verified
Apr 2017
Primary completion
Oct 31, 2008
Completion
Oct 31, 2008

Study Design

Enrollment
38 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Irinotecan Plus Gemcitabine

Locations (1)

FacilityCityStateZIPSite coordinators
Robert H. Lurie Comprehensive Cancer Center at Northwestern UniversityChicagoIllinois60611-

Find similar trials in Chicago, IL

By condition
Bladder cancerBreast cancerColorectal cancerKidney cancerLung cancerPancreatic cancer
By specialty
OncologyUrologyBreast oncologyWomen's healthGI oncologyLung oncologyLung disease
By research site
Robert H. Lurie Comprehensive Cancer Center at Northwestern University· Chicago, IL

Related Studies